Immunotherapy Timing: A Game Changer?

A study suggests that administering immunotherapy infusions before 3 PM significantly improves cancer patient outcomes compared to later infusions. Patients receiving treatment earlier experienced longer disease control (11.3 months vs. 5.7 months) and median survival (at least 23.2 months vs. 16.4 months). This seemingly risk-free and cost-free improvement has sparked debate. While some skepticism remains, multiple retrospective studies and a randomized clinical trial support the finding, suggesting optimal immunotherapy timing may be earlier in the day, potentially linked to the body's circadian rhythm. Further research is needed to understand the mechanism, but this could lead to updated immunotherapy guidelines.